Key facts
- Sichuan Gukang Pharmaceutical’s last known valuation is $12.3M (Jun 2025).
- Notable investors include Peking University, Weiming Angels.
- Status: Acquired/Merged (Operating Subsidiary).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Sichuan Gukang Pharmaceutical
- ·The full record, as it builds
Funding rounds
No funding rounds for Sichuan Gukang Pharmaceutical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Sichuan Gukang Pharmaceutical
Provider of a traditional medicine supply chain service intended for the distribution of Chinese herbal medicine slices. The company offers integrated capabilities in medicinal material cultivation, processing, and slicing, along with research, manufacturing, and sales of standardized herbal components, enabling pharmaceutical producers, healthcare institutions, and wellness distributors to access traceable, high-quality ingredients and formulations for clinical applications, retail channels, and traditional treatment practices.
- Sector
- Healthcare
- HQ
- Dujiangyan, China
- Founded
- 2012
- Employees
- 118
- Website
- gukangyaoye.com/
- Ownership
- Acquired/Merged (Operating Subsidiary)
Sichuan Gukang Pharmaceutical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sichuan Gukang Pharmaceutical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sichuan Gukang Pharmaceutical in its N-PORT filings yet. We sweep new filings monthly.